Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.

Autor: Lebellec L; Lille University Hospital and Medical School, 59045, Lille cedex, France., Bertucci F; Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France., Tresch-Bruneel E; Direction of Research and Innovation, Centre Oscar Lambret, 3 rue Combemale, 59020, Lille cedex, France., Ray-Coquard I; Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France., Le Cesne A; Department of Medical Oncology, Gustave Roussy Institute, 114 Rue Edouard Vaillant, 94800, Villejuif, France., Bompas E; Department of Medical Oncology, Centre René Gauducheau, Boulevard Professeur Jacques Monod, 44805, Saint-Herblain, France., Blay JY; Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France., Italiano A; Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France., Mir O; Department of Medical Oncology, Gustave Roussy Institute, 114 Rue Edouard Vaillant, 94800, Villejuif, France., Ryckewaert T; Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France., Toiron Y; Department of Molecular Pharmacology, Institute Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France., Camoin L; Department of Molecular Pharmacology, Institute Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France., Goncalves A; Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France., Penel N; Lille University Hospital and Medical School, 59045, Lille cedex, France. n-penel@o-lambret.fr.; Direction of Research and Innovation, Centre Oscar Lambret, 3 rue Combemale, 59020, Lille cedex, France. n-penel@o-lambret.fr.; General Oncology Department, Centre Oscar Lambret, Lille, 3 rue Combemale, 59020, Lille cedex, France. n-penel@o-lambret.fr.; Department of Clinical Research and Innovation, Centre Oscar Lambret, 3, rue Combemale, 59020, Lille, France. n-penel@o-lambret.fr., Le Deley MC; Direction of Research and Innovation, Centre Oscar Lambret, 3 rue Combemale, 59020, Lille cedex, France.; Paris-Saclay University, Paris-Sud University, UVSQ, CESP, INSERM, Villejuif, France.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2018 Oct 11; Vol. 18 (1), pp. 963. Date of Electronic Publication: 2018 Oct 11.
DOI: 10.1186/s12885-018-4828-1
Abstrakt: Background: We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel.
Methods: Circulating pro/anti-angiogenic factors were assessed on day 1 (D1) and day 8 (D8). The prognostic value for progression-free survival (PFS) was evaluated using a Cox model with biomarkers as continuous variables.
Results: Among the 51 patients enrolled and treated in this trial, biomarker analysis was performed for 42: 18 in Arm A (single-agent) and 24 in Arm B (combination). With a median follow-up of 46 months, PFS was 5.5 versus 5.7 months, respectively (p = 0.75). According to univariate analysis, factors associated with a poor PFS were as follows: visceral angiosarcoma, de novo angiosarcoma, and high PlGF and low VEGF-C baseline values. In multivariate analysis, de novo angiosarcoma (HR = 2.5; p = 0.024) and baseline VEGF-C value (HR = 0.7; p = 0.003) were significant prognostic factors. We observed a significant increase in circulating PlGF (< 0.001) and a decrease in VEGF (< 0.001) during bevacizumab treatment. An increase in FGF was associated with a poor outcome.
Conclusions: De novo angiosarcoma and a low baseline level of VEGF-C were found to be associated with a poor prognosis. Addition of bevacizumab induces major changes in circulating biomarkers (VEGF and PlGF) in a short timeframe without impacting PFS.
Trial Registration: Retrospectively registered on EudraCT N° 2009-017020-59 and NCT01303497 (February 24, 2011).
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje